Healthcare Industry News: Cook Inc
News Release - March 6, 2006
Medical Team Successfully Retrieves Cook Inc.'s Newest Generation Vena Cava Filter From Patient After 62 DaysBLOOMINGTON, IN--(Healthcare Sales & Marketing Network)--Mar 6, 2006 -- Physicians in Australia have successfully completed the first retrieval of Cook's newest-generation retrievable vena cava filter. The Cook Celect(TM) Vena Cava Filter was used in November on a young trauma patient to minimize the risk of pulmonary embolism. It was retrieved safely 62 days after implantation when the patient's risk of embolism had lessened sufficiently to permit its removal. The procedures were carried out by a team led by the study's two principal investigators, Dr. Stuart Lyon and Dr. Kenneth Thomson, at The Alfred Hospital in Victoria, Australia. Engineered specifically to enhance the filter's retrievability, the Celect vena cava filter is based on Cook's proven Günther Tulip Vena Cava Filter design, one of the world's leading devices of its kind. In animal trials, the Celect filter has been retrieved without difficulty or complication after being implanted for more than one year, which may prove beneficial to human patients whose risk of pulmonary embolism has lessened sufficiently over time to allow the filter to be withdrawn.
"We are extremely pleased to see this patient doing well and that our new vena cava filter performed as designed. Dr. Lyon reported there was no complications with the filter and added that it came out easily," explained Bruce Fleck, global product manager for venous filtration products for Cook Inc. "The Celect filter design builds upon the proven strengths of the Tulip filter while making clinically valuable changes to the secondary struts. With these changes, the Cook Celect filter offers physicians improved centering in the vessel and reduced endothelialization of the filter except at the desired attachment points to enhance its retrievability over extended periods."
The retrieval is the first in an international clinical investigation of the Celect filter. Under the study protocol, the trial will include investigation sites in Germany, Mexico, Australia, Ireland, the United Kingdom, Spain and France.
The world's largest privately held manufacturer of medical devices with international headquarters in Bloomington, Ind., COOK® (www.cookmedical.com/) is a leading designer, manufacturer and global distributor of minimally invasive medical device technology for diagnostic and therapeutic procedures. Since its founding in 1963, Cook has created innovative technologies for drug-eluting and bare metal stents, aortic and vascular endografts, catheters, wire guides, introducer needles and sheaths, embolization coils, medical biomaterials and contract manufacturing of biopharmaceuticals, vena cava filters and other minimally invasive medical devices for radiology, cardiology, urology and women's health, critical care medicine, surgery, gastroenterology, bone access and endovascular therapies.
Source: Cook Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.